United States securities and exchange commission logo




                                                                                
                          June 3, 2024

       Richard Paulson
       President and Chief Executive Officer
       Karyopharm Therapeutics Inc.
       85 Wells Avenue, 2nd Floor
       Newton, MA 02459

                                                        Re: Karyopharm 
Therapeutics Inc.
                                                            Registration 
Statement on Form S-3
                                                            Filed May 30, 2024
                                                            File No. 333-279833

       Dear Richard Paulson:

              This is to advise you that we have not reviewed and will not 
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for 
acceleration. We remind you
       that the company and its management are responsible for the accuracy and 
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of 
action by the staff.

                                                        Please contact Chris 
Edwards at 202-551-6761 with any questions.



                                                                                
                          Sincerely,

                                                                                
                          Division of Corporation Finance
                                                                                
                          Office of Life Sciences
       cc:                                              Craig Hilts